Clinical Trials
9 trialsNCT03607539 2026-05-11
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03812549 2025-03-04
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Sichuan University
Phase 1 Completed
NCT05017103 2024-12-11
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03150875 2023-02-28
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03629925 2023-02-28
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03568539 2021-06-01
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03116152 2021-02-03
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed